RU2004103475A - Производные арил-или гетероарилазолилкарбинолов для лечения недержания мочи - Google Patents
Производные арил-или гетероарилазолилкарбинолов для лечения недержания мочи Download PDFInfo
- Publication number
- RU2004103475A RU2004103475A RU2004103475/15A RU2004103475A RU2004103475A RU 2004103475 A RU2004103475 A RU 2004103475A RU 2004103475/15 A RU2004103475/15 A RU 2004103475/15A RU 2004103475 A RU2004103475 A RU 2004103475A RU 2004103475 A RU2004103475 A RU 2004103475A
- Authority
- RU
- Russia
- Prior art keywords
- methyl
- dimethylamino
- ethoxy
- pyrazole
- thienylmethyl
- Prior art date
Links
- 206010046543 Urinary incontinence Diseases 0.000 title claims 6
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 6
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 6
- -1 thienyl radical Chemical class 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- JLKUMSHHQYQLSG-UHFFFAOYSA-N 3-carboxy-3,5-dihydroxy-5-oxopentanoate;dimethyl-[2-[(2-methylpyrazol-3-yl)-phenylmethoxy]ethyl]azanium Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=NN1C JLKUMSHHQYQLSG-UHFFFAOYSA-N 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- DCMJBKFKXGPPMT-UHFFFAOYSA-N n,n-dimethyl-2-[(2-methylpyrazol-3-yl)-phenylmethoxy]ethanamine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=NN1C DCMJBKFKXGPPMT-UHFFFAOYSA-N 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 239000000460 chlorine Chemical group 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 claims 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (5)
1. Применение производного арил- или гетероарилазолилкарбинола общей формулы I,
в которой Ar представляет собой фенильный радикал или тиенильный радикал без замещений или, при необходимости, с 1, 2 или 3 одинаковыми или разными заместителями, выбранными из группы, состоящей из фтора, хлора, брома, метила, трифторметила и метокси;
R1 представляет собой атом водорода или низшую алкильную группу от C1 до С4;
R2 представляет собой радикал диалкил(С1-С4)аминоалкил(С2-С3) или азагетероциклилалкил(С2-С3) и
Het представляет собой пятичленный азотсодержащий ароматический гетероцикл, который содержит от одного до трех атомов азота, не имеет заместителей или, при необходимости, замещен 1 или 2 одинаковыми или разными заместителями, выбранными из группы, состоящей из фтора, хлора, брома и метила;
или одной из его физиологически приемлемых солей при получении лекарственного средства для лечения недержания мочи у млекопитающих, включая человека.
2. Применение по п.1 соединения общей формулы (I), в которой R1 выбран из атома водорода или из группы, состоящей из метила, этила, пропила, изопропила, бутила, изобутила, втор-бутила и трет-бутила, при получении лекарственного средства для лечения недержания мочи у млекопитающих, включая человека.
3. Применение по п.1 соединения общей формулы (I), в которой R2 выбран из группы, состоящей из диметиламиноэтила, диметиламинопропила, диэтиламиноэтила, пиперидинилэтила, морфолинилпропила и пирролидинилэтила, при получении лекарственного средства для лечения недержания мочи у млекопитающих, включая человека.
4. Применение по п.1 соединения общей формулы (I), выбранного из группы, состоящей из:
(±)-5-{α-[2-(диметиламино)этокси]бензил}-1-метил-1H-пиразола,
цитрата (±)-5-{α-[2-(диметиламино)этокси]бензил}-1-метил-1Н-пиразола,
(+)-5-{α-[2-(диметиламино)этокси]бензил}-1-метил-1Н-пиразола,
(-)-5-{α-[2-(диметиламино)этокси]бензил}-1-метил-1Н-пиразола,
цитрата (+)-5-{α-[2-(диметиламино)этокси]бензил}-1-метил-1Н-пиразола,
цитрата (-)-5-{α-[2-(диметиламино)этокси]бензил}-1-метил-1Н-пиразола,
(±)-5-{α-[2-(диметиламино)этокси]-2-тиенилметил}-1-метил-1Н-пиразола,
цитрата (±)-5-{α-[2-(диметиламино)этокси]-2-тиенилметил}-1-метил-1Н-пиразола,
(+)-5-{α-[2-(диметиламино)этокси]-2-тиенилметил}-1-метил-1Н-пиразола,
(-)-(±)-5-{α-[2-(диметиламино)этокси]-2-тиенилметил}-1-метил-1Н-пиразола,
цитрата (+)-5-{α-[2-(диметиламино)этокси]-2-тиенилметил}-1-метил-1Н-пиразола,
цитрата (-)-5-{α-[2-(диметиламино)этокси]-2-тиенилметил}-1-метил-1Н-пиразола,
при получении лекарственного средства для лечения недержания мочи у млекопитающих, включая человека.
5. Фармацевтическая композиция, характеризующаяся тем, что она содержит, по меньшей мере, одно соединение общей формулы (I) или одну из его физиологически приемлемых солей по любому из пп.1-4 и фармацевтически приемлемые наполнители, для лечения недержания мочи у млекопитающих, включая человека.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP200101587 | 2001-07-06 | ||
ES200101587A ES2180449B1 (es) | 2001-07-06 | 2001-07-06 | Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de la incontinencia urinaria. |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2004103475A true RU2004103475A (ru) | 2005-06-10 |
RU2308268C2 RU2308268C2 (ru) | 2007-10-20 |
Family
ID=8498326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2004103475/15A RU2308268C2 (ru) | 2001-07-06 | 2002-07-01 | Производные арил- или гетероарилазолилкарбинолов для лечения недержания мочи |
Country Status (23)
Country | Link |
---|---|
US (2) | US20030022925A1 (ru) |
EP (1) | EP1413305B1 (ru) |
JP (1) | JP2004521150A (ru) |
KR (1) | KR20040030788A (ru) |
CN (1) | CN1543344A (ru) |
AR (1) | AR034679A1 (ru) |
AT (1) | ATE327752T1 (ru) |
BR (1) | BR0211237A (ru) |
CA (1) | CA2452646A1 (ru) |
CY (1) | CY1105113T1 (ru) |
DE (1) | DE60211913T2 (ru) |
DK (1) | DK1413305T3 (ru) |
ES (2) | ES2180449B1 (ru) |
MA (1) | MA27056A1 (ru) |
MX (1) | MXPA04000065A (ru) |
NO (1) | NO20040031L (ru) |
NZ (1) | NZ530817A (ru) |
PL (1) | PL369062A1 (ru) |
PT (1) | PT1413305E (ru) |
RU (1) | RU2308268C2 (ru) |
UA (1) | UA79238C2 (ru) |
WO (1) | WO2003004022A1 (ru) |
ZA (1) | ZA200400780B (ru) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040142929A1 (en) * | 2001-07-06 | 2004-07-22 | Ramon Merce-Vidal | Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence |
DE10335566A1 (de) * | 2003-07-31 | 2005-02-24 | Grünenthal GmbH | Arzneimittel enthaltend Derivate von Aryl( oder Heteroaryl)azolylcarbinolen |
TW200533657A (en) * | 2004-02-17 | 2005-10-16 | Esteve Labor Dr | Substituted pyrazoline compounds, their preparation and use as medicaments |
ES2244326B1 (es) * | 2004-04-05 | 2007-02-16 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de substancias activas. |
EP1584335A3 (en) * | 2004-04-05 | 2006-02-22 | Laboratorios Del Dr. Esteve, S.A. | Active substance combination comprising a carbinol composition and an opioid |
US20060040924A1 (en) * | 2004-06-22 | 2006-02-23 | Laboratorios Dr. Esteve S.A. | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of renal colic |
WO2006010627A1 (en) * | 2004-07-30 | 2006-02-02 | Laboratorios Del Dr. Esteve, S.A. | Aryl (or heteroaryl) azolylcarbinols |
EP1743892A1 (en) * | 2005-07-15 | 2007-01-17 | Laboratorios del Dr. Esteve S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
EP1743890A1 (en) * | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments |
US7897589B2 (en) * | 2005-07-15 | 2011-03-01 | Laboratorios Del Dr. Esteve, S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
EP1757587A1 (en) * | 2005-07-15 | 2007-02-28 | Laboratorios Del Dr. Esteve, S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
US20070021485A1 (en) * | 2005-07-22 | 2007-01-25 | Gomis Antonio F | Aryl (or heteroaryl) azolylcarbinols |
ES2334548B1 (es) * | 2005-07-29 | 2010-10-27 | Laboratorios Del Dr. Esteve, S.A | Forma de dosificacion de liberacion controlada de compuestos de pirazol para el tratamiento de la incontinencia urinaria. |
US8722079B2 (en) | 2008-04-18 | 2014-05-13 | Warsaw Orthopedic, Inc. | Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine |
EP2151234A1 (en) * | 2008-07-28 | 2010-02-10 | Laboratorios Del. Dr. Esteve, S.A. | Pharmaceutical formulation comprising a CB1-receptor compound in a solid solution and/or solid dispersion |
US20100291151A1 (en) * | 2009-04-21 | 2010-11-18 | Auspex Pharmaceuticals, Inc. | 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE891865A (fr) * | 1981-01-30 | 1982-07-22 | Sandoz Sa | Nouveaux medicaments a base de derives condenses de l'imidazole pour le traitement des troubles urinaires |
ES2150353B1 (es) * | 1998-04-15 | 2001-07-01 | Esteve Labor Dr | Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos. |
ES2137136B1 (es) * | 1998-05-18 | 2000-07-01 | Esteve Labor Dr | Empleo de derivados de aril (o heteroaril) azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de la inflamacion neurogenica. |
ES2150378B1 (es) * | 1998-08-07 | 2001-07-01 | Esteve Labor Dr | Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p. |
-
2001
- 2001-07-06 ES ES200101587A patent/ES2180449B1/es not_active Expired - Fee Related
-
2002
- 2002-01-07 UA UA2004020880A patent/UA79238C2/uk unknown
- 2002-07-01 PL PL02369062A patent/PL369062A1/xx not_active Application Discontinuation
- 2002-07-01 KR KR10-2004-7000056A patent/KR20040030788A/ko not_active Application Discontinuation
- 2002-07-01 WO PCT/ES2002/000326 patent/WO2003004022A1/es active IP Right Grant
- 2002-07-01 AR ARP020102482A patent/AR034679A1/es not_active Application Discontinuation
- 2002-07-01 MX MXPA04000065A patent/MXPA04000065A/es unknown
- 2002-07-01 EP EP02745440A patent/EP1413305B1/en not_active Expired - Lifetime
- 2002-07-01 CN CNA028161009A patent/CN1543344A/zh active Pending
- 2002-07-01 BR BR0211237-0A patent/BR0211237A/pt not_active IP Right Cessation
- 2002-07-01 AT AT02745440T patent/ATE327752T1/de not_active IP Right Cessation
- 2002-07-01 CA CA002452646A patent/CA2452646A1/en not_active Abandoned
- 2002-07-01 DE DE60211913T patent/DE60211913T2/de not_active Expired - Fee Related
- 2002-07-01 JP JP2003510033A patent/JP2004521150A/ja active Pending
- 2002-07-01 NZ NZ530817A patent/NZ530817A/en unknown
- 2002-07-01 PT PT02745440T patent/PT1413305E/pt unknown
- 2002-07-01 RU RU2004103475/15A patent/RU2308268C2/ru not_active IP Right Cessation
- 2002-07-01 ES ES02745440T patent/ES2263792T3/es not_active Expired - Lifetime
- 2002-07-01 DK DK02745440T patent/DK1413305T3/da active
- 2002-07-03 US US10/189,915 patent/US20030022925A1/en not_active Abandoned
-
2004
- 2004-01-05 NO NO20040031A patent/NO20040031L/no not_active Application Discontinuation
- 2004-01-30 ZA ZA200400780A patent/ZA200400780B/en unknown
- 2004-02-04 MA MA27514A patent/MA27056A1/fr unknown
-
2005
- 2005-01-28 US US11/045,708 patent/US20050131049A1/en not_active Abandoned
-
2006
- 2006-07-28 CY CY20061101049T patent/CY1105113T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
JP2004521150A (ja) | 2004-07-15 |
RU2308268C2 (ru) | 2007-10-20 |
KR20040030788A (ko) | 2004-04-09 |
ES2180449B1 (es) | 2004-01-16 |
NZ530817A (en) | 2005-07-29 |
PL369062A1 (en) | 2005-04-18 |
NO20040031L (no) | 2004-03-02 |
ES2263792T3 (es) | 2006-12-16 |
ATE327752T1 (de) | 2006-06-15 |
EP1413305B1 (en) | 2006-05-31 |
US20030022925A1 (en) | 2003-01-30 |
CA2452646A1 (en) | 2003-01-16 |
BR0211237A (pt) | 2004-08-10 |
DE60211913D1 (de) | 2006-07-06 |
ZA200400780B (en) | 2005-01-31 |
MXPA04000065A (es) | 2004-05-21 |
EP1413305A1 (en) | 2004-04-28 |
DK1413305T3 (da) | 2006-09-18 |
MA27056A1 (fr) | 2004-12-20 |
ES2180449A1 (es) | 2003-02-01 |
CN1543344A (zh) | 2004-11-03 |
UA79238C2 (en) | 2007-06-11 |
CY1105113T1 (el) | 2010-03-03 |
DE60211913T2 (de) | 2007-05-24 |
US20050131049A1 (en) | 2005-06-16 |
WO2003004022A1 (es) | 2003-01-16 |
PT1413305E (pt) | 2006-09-29 |
AR034679A1 (es) | 2004-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2004103475A (ru) | Производные арил-или гетероарилазолилкарбинолов для лечения недержания мочи | |
RU2007116119A (ru) | Производные циклоспорина, замещенные 3-эфиром и 3-тиоэфиром, для лечения и профилактики инфекционного гепатита с | |
JP2006515339A5 (ru) | ||
IL175716A (en) | 2- (4-Bromo- or 4-Methyl-Phenylamino) -6-Oxo-1,6-Dihydropyridines and their use in drug preparation | |
RU2002123350A (ru) | Дипептиднитрильные ингибиторы катепсина К | |
ES2295609T3 (es) | Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor. | |
JP2008514732A5 (ru) | ||
KR960701033A (ko) | 효능있는 칼슘 길항 및 산화방지 활성을 모두 갖는 화합물, 및 세포보호제로서 그것의 사용방법(compounds having both potent calcium antagonist and antioxidant activity and use there of as cytoprotective agents) | |
RU2002107975A (ru) | Глюкопиранозилоксипиразольные производные, лекарственные композиции, содержащие эти производные, и промежуточные соединения для их получения | |
DK2314582T3 (da) | Heterocykliske forbindelser som antivirusmidler | |
JP2004521150A5 (ru) | ||
RU2002124873A (ru) | Глюкопиранозилоксибензилбензольные производные, лекарственные композиции, содержащие эти производные, и промежуточные соединения для получения указанных производных | |
NO20045103L (no) | Benzofuserte heteroarylamid-derivater av thienopyridiner anvendelige som terapeutiske midler, farmasoytiske blandinger omfattende de samme og fremgangsmater for deres anvendelse | |
KR950016745A (ko) | 생리증상의 치료방법 및 이를 위한 조성물 | |
CA2617817A1 (en) | Thiazole derivatives for treating or preventing sleep disorders | |
ATE384058T1 (de) | Thiazolderivate | |
JP2006501201A5 (ru) | ||
IL184116A0 (en) | Use of thiazolidinone derivatives as antiangiogenic agents | |
DE60014916D1 (de) | Die Verwendung eines Benzimidazoles zur Herstellung eines Medikamentes zur Krebsvorbeugung | |
DK1228758T3 (da) | Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom | |
EA019037B1 (ru) | 5-[5-[2-[3,5-бис(трифторметил)фенил-2-метилпропаноилметиламино]-4-(4-фтор-2-метилфенил)]-2-пиридинил]-2-алкилпролинамиды в качестве антагонистов рецептора nk1 | |
RU2004104329A (ru) | Ацилсемикарбазиды как ингибиторы циклинзависимой киназы, полезные в качестве противораковых и противопролиферативных агентов | |
ATE358128T1 (de) | Vorbeugende oder therapeutische mittel gegen gastrische oder ösophageale regurgitation | |
RU2000131615A (ru) | Применение производных арил(или гетероарил)азолилкарбинолов в производстве препарата для лечения нейрогенного воспаления | |
CA2510468A1 (en) | Novel 2,4-diamino-1,3,5-triazine derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20080702 |